The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

• DOI: 10.18632/oncotarget.18746
• Publication Date: 2017-06-28T11:15:09Z
• Authors: Chien-Ying Liu; Chih-Liang Wang; Shih-Hong Li; Ping-Chih Hsu; Chih-Hung Chen; Ting-Yu Lin; Chih-Hsi Kuo; Yueh-Fu Fang; How-Wen Ko; Chih-Teng Yu; Tai-Yun Yang; Cheng-Ta Yang
• Keywords: Afatinib; Discontinuation; Regimen

The choice of a first-line therapy for lung cancer is crucial decision that can impact the survival as well quality life patient. Inhibitors epidermal growth factor receptor (EGFR) such afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell harboring favorable EGFR mutations. Although afatinib has greater efficacy than other inhibitors, adverse events related its use result in discontinuation therapy. In this study, we compared therapeutic patients regimen 40 mg/day with lower dose <40 resulting either from starting 30 or adjustment. Seventy-nine were treated 67 received de-escalated doses mg/day. There was no significant difference clinical characteristics two groups except proportion body weight 50 kg more group. Otherwise, there differences between average time treatment failure (TTF), rates at which administration second-line necessary, frequency severity events. Overall, these results suggest it possible calibrate dosage suit individual patient parameters low weight, calibration be advised based on given patient's experience drug.